Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery

Table 1 Baseline characteristics of patients who underwent follow-up coronary angiography

Characteristics	MT (n= 110)	PCI (n= 146)	CABG (n= 136)	p
Demographic profile
Age, y	59 ± 9	60 ± 9	61 ± 10	0.147
Female (%)	29	35	26	0.286
Medical history (%)
Current Smoker	32	27	31	0.018
Hypertension	55	60	63	0.016
Diabetes mellitus	35	29	42	0.090
CCS class I or III angina	79	92	88	0.012
Laboratory values, mmol/L
Total cholesterol	224 ± 39	227 ± 49	210 ± 43	0.007
LDL cholesterol	151 ± 34	151 ± 88	140 ±37	0.032
HDL cholesterol	37 ± 9	38 ± 10	36 ± 10	0.600
Triglycerides	200 ± 136	189 ± 94	181 ± 109	0.348
Medications
Beta-blockers	79	79	86	0.209
Calcium-channel antagonists	62	42	66	0.001
Long-acting nitrates	90	84	82	0.0195
ACE inhibitors	35	33	28	0.467
HMG-CoA reductase inhibitors	26	16	13	0.024
Aspirin	97	98	96	0.719
Oral Hypoglycemic agents	14	8	12	0.333
Insulin	16	16	11	0.649
Positive treadmill test %	75	72	71	0.766
Entry angiographic features
Mean ejection fraction	66 ± 25	67 ± 17	66 ± 19	0.328
Double-vessel disease, %	46	45	60	0.654
Triple-vessel disease, %	54	55	50	0.648
Proximal LAD, %	88	90	91	0.232
Vessel Territory ≥ 70%, %
Left anterior descending	89	93	95	0.062
Left circumflex	71	70	78
Right coronary artery	71	68	85
Risk factor control at 5 years
Aspirin use, %	95	94	95	0.926
Lipid-lowering drug, %	78	81	66	0.009
Current smoker, %	22	16	12	0.023
Total Events
New intervention	24.2	32.2	3.5	0.001
Acute myocardial infarction	6	11	6	0.224
Stroke	2	3	2	0.884
Angina at 5 years	45.2	22.8	25.8	0.001

MT = medical treatment; PCI = percutaneous coronary intervention; CABG=coronary artery bypass graft; LAD = left anterior descending artery; ACE = angiotensin-converting enzyme, HMG-CoA = 3-hydroxy-3methylglutaryl-coenzyme-a, LDL and HDL = high- and low-density lipoprotein, respectively.

ISSN: 1749-8090